Carlos Fonte, MD
Cardiovascular Disease · Las Vegas, NVNPI 1215979604
Payments from drug & device makers
Across 371 payments — averaging $20.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Johnson & Johnson$1K
- Novartis$880
- AstraZeneca$543
- Sanofi-aventis U.S. LLC$410
- Boehringer Ingelheim$406
- plus $3K from 26 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 56 | $1,599 |
| Johnson & Johnson | 80 | $1,190 |
| Novartis | 53 | $880 |
| AstraZeneca | 9 | $543 |
| Sanofi-aventis U.S. LLC | 22 | $410 |
| Boehringer Ingelheim | 22 | $406 |
| E.r. Squibb & Sons, L.L.C. | 19 | $367 |
| Merck | 15 | $272 |
| Nevro Corp. | 3 | $240 |
| Amarin Pharma, Inc. | 14 | $224 |
| Medtronic(2 entities) | 6 | $223 |
| Impulse Dynamics (USA) Inc. | 3 | $174 |
| Bayer | 8 | $141 |
| Esperion Therapeutics, Inc. | 8 | $139 |
| Abbott | 6 | $112 |
| Pfizer | 7 | $107 |
| Astellas Pharma US Inc | 6 | $99 |
| Novo Nordisk | 5 | $96 |
| Alnylam Pharmaceuticals Inc. | 3 | $89 |
| Boston Scientific | 5 | $83 |
| Bard Peripheral Vascular, Inc. | 4 | $72 |
| Kowa Pharmaceuticals America, Inc. | 4 | $61 |
| Irhythm Technologies, Inc. | 3 | $46 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $42 |
| Scpharmaceuticals Inc. | 1 | $33 |
| Edwards Lifesciences | 1 | $32 |
| Lundbeck LLC | 1 | $25 |
| Bardy Diagnostics, Inc. | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
| Koya Medical, Inc. | 1 | $15 |
| Tactile Systems Technology Inc | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
How this compares
$7,782 in reported general payments places this provider in the 65th percentile of 165 cardiovascular disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Las Vegas
- Ramprasad DandillayaLas Vegas$1.8M
- Chowdhury AhsanLas Vegas$1.4M
- Arjun GururajLas Vegas$399K
- Navid KazemiLas Vegas$156K
- Branavan UmakanthanLas Vegas$109K
- Sanjay MalhotraLas Vegas$101K
- Jawad KianiLas Vegas$73K
- Amish PrasadLas Vegas$58K
- Rafael ValenciaLas Vegas$52K
- Salvador BorromeoLas Vegas$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.